Last reviewed · How we verify
TR-701 FA
TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome.
TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).
At a glance
| Generic name | TR-701 FA |
|---|---|
| Also known as | Tedizolid Phosphate, TR-700 active moiety, Tedizolid |
| Sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | Oxazolidinone antibiotic |
| Target | Bacterial 70S ribosome |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
TR-701 FA (tedizolid phosphate) is rapidly converted to TR-700 (tedizolid) in vivo. TR-700 is an oxazolidinone antibiotic that binds to the bacterial 70S ribosome and inhibits protein synthesis, making it effective against gram-positive bacteria including multidrug-resistant pathogens. It has enhanced potency and improved pharmacokinetics compared to linezolid, the parent oxazolidinone class drug.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
- Community-acquired bacterial pneumonia (CABP)
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
- Peripheral neuropathy
Key clinical trials
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
- A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) (PHASE1)
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (PHASE1)
- Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg (PHASE1)
- Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) (PHASE3)
- Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients (PHASE1)
- A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects (PHASE1)
- A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: